外媒:中國癌症研究取得突破

▲全球視野 本土思考

癌症仍然是中國的重點疾病之一。

惠譽國際諮詢公司(Fitch Solutions)的一份展望報告稱，隨著中國在先進癌症治療方法的早期取得突破，中國將繼續在抗癌藥物的研究和治療方面進行創新。

其中一些進展包括單克隆抗體和CAR-T療法的進展。

中國生物科技初創企業越來越多，從2013年到2018年，中國的生命科學投資增長了1,287％。

當美國食品和藥物管理局於2019年11月授權百濟神州公司獨立開發的Brukinsa（zanubrutinib）時，標誌著中國抗癌藥物的首次批准。

今年早些時候，該公司的抗pd -1抗體tislelizumab也獲得了中國國家醫藥產品管理局的批准。

癌症仍是中國的五大重點疾病領域之一，2018年全球癌症病例數最高，達到每年400萬例。該國的癌症死亡率也比美國高40%。

同時，中國政府對醫療保健政策進行了幾項改革，以控制發病率的上升，包括實施抗癌藥物零關稅政策，接受海外臨床試驗數據以及以及採取措施加快癌症藥物審批。＊

China sees breakthroughs in cancer research

Cancer remains amongst China’s high-priority disease areas.

China continues to innovate on their anti-cancer drug research and treatment as they make early breakthroughs in therapies derived from advanced cancer treatments, according to an outlook by Fitch Solutions.

Some of these developments include advances in monoclonal antibodies and CAR-T therapies.

Amidst a growing number of biotech start-ups in the country, China saw a 1,287% growth in life science investment from 2013 to 2018.

The country marked its first-ever approval for a Chinese anti-cancer drug when the US Food and Drug Administration authorized BeiGene’s independently developed Brukinsa (zanubrutinib) in November 2019. The company’s anti-PD-1 antibody tislelizumab was also approved by China's National Medical Products Administration earlier this year.

Cancer remains amongst China’s five high-priority disease areas, with them having the largest number of cases globally at four million per year in 2018. The country’s cancer mortality rate is also 40% higher than that of the US.

Meanwhile, the Chinese government has made several reforms on healthcare policy to manage the rising rates of incidence, including the implementation of a zero-tariff policy on anti-cancer drugs, acceptance of overseas clinical trial data, and adoption of measures to speed up the approval of cancer medicines.